Synthorx Agrees to Sell to Sanofi for $2.5 Billion

San Diego – December 9, 2019 – Cooley advised clinical-stage biotechnology company Synthorx on its agreement to sell to Sanofi for approximately $2.5 billion. Partners Barbara Borden, Rama Padmanabhan and Ken Rollins led the Cooley team advising Synthorx.

Under the terms of the agreement, Sanofi will acquire all outstanding shares of Synthorx for $68 per share in cash. The transaction has been unanimously approved by both the Sanofi and Synthorx boards of directors and is expected to close in Q1 2020.

“We are grateful that Sanofi has acknowledged the value of our expanded genetic alphabet platform and the potential of our pipeline of optimized therapeutics for cancer and autoimmune disorders,” Laura Shawver, president and CEO of Synthorx, said in a statement.

Synthorx focuses on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. The company’s proprietary, first-of-its-kind expanded genetic alphabet platform technology broadens the genetic code by adding a new DNA base pair. Alone and in combination with other existing Sanofi platforms, the technology will enable development of a range of novel biologics.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.